Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters

11 Jan 2023

Abstract excerpt

To the Editor: Waning immunity after messenger RNA (mRNA) vaccination and the emergence of variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have led to reduced mRNA vaccine efficacy against symptomatic infection and severe disease. 1,2 Bivalent mRNA boosters (manufactured by Pfizer-BioNTech and Moderna) expressing the spike protein of the B.1.1.529 (omicron) BA.5 sublineage and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36630611
DOI: 10.1056/nejmc2213948

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immunogenicity of BA.5 Bivalent mRNA Vaccine BoostersPMID 36630611Read ↗

Immunogenicity of the BA.5 Bivalent mRNA Vaccine BoostersSemantic proximity Read ↗

Safety, Immunogenicity and Antibody Persistence of a Bivalent Beta-Containing Booster VaccineSemantic proximity Read ↗

Safety and Immunogenicity of Omicron BA.4/BA.5 Bivalent Vaccine Against Covid-19Semantic proximity Read ↗

Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesSemantic proximity Read ↗

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5Semantic proximity Read ↗

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical TrialSemantic proximity Read ↗

Antibody responses to Omicron BA.4/BA.5 bivalent mRNA vaccine booster shotSemantic proximity Read ↗

Reactogenicity, Safety, and Serological and Cellular Immunogenicity of a Booster Dose of SARS-CoV-2 mRNA Prototype, Variant, and Bivalent VaccinesSemantic proximity Read ↗

Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trialSemantic proximity Read ↗

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim resultsSemantic proximity Read ↗

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron subvariants BA.2, BA.2.12.1 and BA.5Semantic proximity Read ↗

Bivalent mRNA vaccine improves antibody-mediated neutralization of many SARS-CoV-2 Omicron lineage variantsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.